Chemistry:Fluperlapine

From HandWiki
Revision as of 02:37, 9 March 2024 by AIposter (talk | contribs) (add)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Fluperlapine
Fluperlapine.svg
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC19H20FN3
Molar mass309.388 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Fluperlapine (NB 106-689), also known as fluoroperlapine, is a morphanthridine (11H-dibenzo[b,e]azepine) atypical antipsychotic with additional antidepressant and sedative effects. It was first synthesized in 1979, and then subsequently studied in animals and humans in 1984 and beyond,[1] but despite demonstrating efficacy in the treatment of a variety of medical conditions including schizophrenia,[2][3][4][5] psychosis associated with Parkinson's disease,[6] depressive symptoms, and dystonia,[7] it was never marketed.[1] This was perhaps due to its capacity for producing potentially life-threatening agranulocytosis, similarly to clozapine,[8] which it closely resembles both structurally and pharmacologically.

Pharmacology

Binding profile[9]

Receptor Ki (nM)
5-HT2A 7.9
5-HT2C 18.2
5-HT6 29
5-HT7 4.6
M1 8.8
M2 71
M3 41
M4 14
M5 17
D1 85
D2 316.2
D3 254.7
D4 21

Synthesis

Error creating thumbnail: Unable to save thumbnail to destination
Patents:[10][11]

3-fluoro-5,11-dihydro-6H-dibenz[b,e]azepin-6-one [62662-88-8] (3)

See also

References

  1. 1.0 1.1 Dictionary of pharmacological agents. CRC Press. 1997. p. 916. ISBN 978-0-412-46630-4. https://books.google.com/books?id=DeX7jgInYFMC&pg=PA916. Retrieved 15 September 2011. 
  2. "Fluperlapine in 104 schizophrenic patients. Open multicenter trial". Arzneimittel-Forschung 34 (1A): 125–30. 1984. PMID 6145428. 
  3. "Antipsychotic efficacy of fluperlapine. An open multicenter trial". Neuropsychobiology 11 (2): 116–20. 1984. doi:10.1159/000118064. PMID 6148712. 
  4. "The effect of fluperlapine in acute psychotic patients". Pharmacopsychiatry 17 (2): 57–60. March 1984. doi:10.1055/s-2007-1017408. PMID 6728910. 
  5. "Results of a multicenter AMDP study with fluperlapine in schizophrenic patients". Arzneimittel-Forschung 34 (1A): 122–4. 1984. PMID 6145427. 
  6. "Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine". European Archives of Psychiatry and Neurological Sciences 235 (1): 60–4. 1985. doi:10.1007/bf00380972. PMID 2864254. 
  7. "Medical treatment of dystonia". Dyskinesia. Psychopharmacology Supplementum. 2. 1985. pp. 111–7. doi:10.1007/978-3-642-70140-5_14. ISBN 978-3-642-70142-9. OCLC 10642795. 
  8. "Bioactivation and covalent binding of hydroxyfluperlapine in human neutrophils: implications for fluperlapine-induced agranulocytosis". Drug Metabolism and Disposition 28 (3): 255–63. March 2000. PMID 10681368. 
  9. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. 12 January 2011. http://pdsp.med.unc.edu/pdsp.php. 
  10. Fritz Hunziker, Rudolf Fischer, U.S. Patent 4,308,207 (1981 to Sandoz Ltd.).
  11. Fritz Hunziker & Rudolf Fischer, U.S. Patent 4,406,900 (1983 to Fidelity Union Bank).